April 24, 2011

The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis

.   .   

This population-based study using administrative data showed that 86% of patients on dual ACE inhibitor and angiotensin-II receptor blocker therapy did not have established indications, such as CHF or proteinuria.  Renal dysfunction and hyperkalemia was more common in the combination group, re-emphasizing what has already been shown in randomized controlled trials.

Related Articles:

RAS Blockade

Comments are closed.